{
    "nctId": "NCT00637897",
    "briefTitle": "Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer",
    "officialTitle": "Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes or Ixabepilone for Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "Clinical feasibility of therapy administration",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Histologically confirmed invasive breast cancer\n\n  * Metastatic or recurrent disease\n  * Patients with bone metastasis only are eligible and evaluable for time to progression\n* Candidate for taxane or ixabepilone therapy\n* At least one lesion that can be measured in at least one diameter \u2265 2 cm by CT scan\n* No symptomatic brain metastases or other symptomatic CNS metastases\n* ECOG performance status 0 or 1\n* Life expectancy \\> 3 months\n* ANC \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Hemoglobin \u2265 9 g/dL\n* Serum creatinine \u2264 2.0 mg/dL\n* Total bilirubin \u2264 2.0 g/dL\n* Albumin corrected serum calcium \\< 10.5 mg/dL\n* Fertile patients must use effective contraception during and for at least 1 year after study participation\n* At least 2 weeks since prior chemotherapy or radiation therapy\n* Prior and concurrent taxane or ixabepilone therapy allowed\n* Concurrent oral multivitamins allowed (i.e., Centrum or One a Day)\n* Concurrent bisphosphonates allowed\n\nExclusion Criteria\n\n* History of allergy to calcitriol, paricalcitol, or other Vitamin D compounds\n* History of drug or alcohol abuse within the past 6 months\n* History of other malignancy except inactive nonmelanoma skin cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or other cancer if the patient has been disease-free for 5 or more years\n* Serious medical illness that would limit survival to \\< 3 months\n* Active, uncontrolled bacterial, viral or fungal infection\n* Poorly controlled diabetes\n* Concurrent supplemental calcium\n* Concurrent digitalis compounds\n* Concurrent chemotherapy\n* Concurrent biologic therapy, including trastuzumab and bevacizumab\n* Concurrent hormonal agents for breast cancer except luteinizing hormone-releasing hormone agonists",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}